Palivizumab Drug Information
Palivizumab (Synagis®) is a medication licensed for the prevention of serious complications that can occur in some infants and children who get a respiratory syncytial virus (RSV) infection. This prescription medicine is not approved to prevent an RSV infection, but it can prevent an infection from becoming severe enough to cause problems in infants and children.
This medicine is normally given to infants and children age 24 months or younger who have high-risk factors for RSV, such as those who are premature or have certain types of lung or heart disease. It comes as an injection that is given once a month during the RSV season, which usually runs from November to April.
Before your child receives palivizumab, make sure his or her healthcare provider has up-to-date information on any other drugs your child is taking (including vitamins and supplements), as well as any allergies, including to medications, foods, dyes, or preservatives.
(For more information on this drug, click Palivizumab. This full-length article provides information on how this medicine works, dosing guidelines, and general safety precautions to be aware of before beginning treatment.)